The company attributed the increase to gains in its molecular business, including $7.4 million in revenues from Nanosphere, which Luminex acquired in June.
The company attributed the uptick in revenues to a 100 percent increase in the number of Cologuard colon cancer tests it completed during the quarter.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
The company missed its expectations due to declining orders for its HiSeq 2500 and HiSeq 4000 instruments and one fewer order for its HiSeq X Ten system.
Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.
The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.
After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
The firm completed its acquisition of Nanosphere on June 30, and received FDA clearance and CE-IVD marking for the Aries M1 system on July 6.
The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.